Ex-HHS official: HIPAA must keep up with mobile health

Cara Livernois | | Health Exec | Policy & Regulations

The federal regulatory environment has lagged behind the progress of mobile health. Consumer expect to have all sorts of information, including health data, on their phones, said Jeffrey Dunifon, an associate attorney who previously was an investigator at the Department of Health and Human Services Office for Civil Rights.

To help healthcare provider organizations and mobile developers navigate the HIPAA waters, Dunifon points to the HIPAA Questions Portal at hipaaqsportal.hhs.gov, which was launched by HHS. Providers and developers ask questions, HHS provides answers, said Dunifon, who spoke at the HIMSS and Healthcare IT News Privacy & Security Forum.

Read more by following the link below:

How HIPAA applies to the burgeoning world of mobile health

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.